<DOC>
	<DOCNO>NCT01277315</DOCNO>
	<brief_summary>Amyotrophic Lateral Sclerosis ( ALS ) adult neurodegenerative disease cause selective degeneration motor nerve cell cortex myelon . As result motor neurodegeneration , progredient paralysis extremity speak , swallow , breathe musculature develop . ALS lead death respiratory insufficiency mean course 3-5 year . So far , Riluzole approve neuroprotective medication effect slight lifespan prolongation 1.5 - 2.5 month . Riluzole inhibit presynaptic glutamate release lower level glutamate liberate activated microglia . The researcher propose investigational therapy ALS subcutaneous administration 100 mg Anakinra . The neuronal inflammation crucial pathogenetic factor motor neuron degeneration . Inflammatory process detectable sporadic ALS , autosomal-dominant form ALS transgenic mouse model . The rationale clinical trial base anti-inflammatory effect Anakinra . One key mediator inflammatory response Interleukin-1 . Anakinra recombinant produce Interleukin-1 receptor antagonist . This give Anakinra anti-inflammatory attribute presumably reduce motor neuron degeneration disease progression .</brief_summary>
	<brief_title>Safety Tolerability Anakinra Combination With Riluzol Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>Open Safety Tolerability study evaluate subcutaneous application 100 mg Anakinra combination Riluzol Amyotrophic Lateral Sclerosis .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Patients 18 80 year age Clinical diagnosis amyotrophic lateral sclerosis predominant affection lower motor neuron clinical ALS variant progressive muscular atrophy ( PMA ) Clinical sign low motor neuron degeneration least one anatomic region beyond brain stem Sporadic familial ALS Onset paresis six month four year study inclusion Treatment riluzol 100mg/d least 1 month study inclusion Diagnosis amyotrophic lateral sclerosis predominant affection upper motor neuron without clinical sign concurrent affection lower motor neuron least one anatomic region beyond brain stem ( spastic ALS ) Diagnosis primary lateral sclerosis ( PLS ) Patients know intolerance anakinra , riluzol one additives Clinically severe hypoventilation syndrome vital capacity &lt; 50 % Pregnancy breastfeed Continuous noninvasive ventilation ventilatorfree time &lt; 2 hour Tracheotomy mechanical ventilation Laboratory parameter outside normal range correspond clinically severe cardiovascular , pulmological , hematological , hepatological , metabolic renal disease Malignancies Severe renal insufficiency ( creatinine clearance &lt; 30 ml/min ) History recurrent infection disease may predispose infection Severe neutropenia ( absolute neutrophil count &lt; 1.5 x 109/l ) Monoclonal gammopathy unknown significance Infections include infection HIV hepatitis B C Dementia unable give inform consent History epilepsy epileptic seizure Contraindication E coliderived protein , anakinra component product Concurrent therapy anakinra etanercept TNF block agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>ALS</keyword>
	<keyword>Anakinra</keyword>
	<keyword>Kineret</keyword>
	<keyword>Progressive Muscular Atrophy</keyword>
	<keyword>PMA</keyword>
	<keyword>Safety Trial</keyword>
	<keyword>Tolerability Trial</keyword>
</DOC>